Log inTry free

Atea Pharmaceuticals (AVIR) stock

Market cap $409M

$5.13
+0.59%

Market closed. Prices as of today's close.

Quality Score
3
Below Average
In its industry
#96of 300
Biotech
NextQ1 2027“Topline results are expected in early Q1 2027…”Trial data · 8-K, Aug 12
Cash$219M, about 5 quarters at the last year's spendingOn Jun 30 · the company says “through 2027”

Follow AVIR's trial news. Pro members can get an alert when Atea Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when AVIR files news on its trialsFree for 24 hours. No account needed.
Cash$219M, about 5 quarters at the last year's spendingOn Jun 30 · the company says “through 2027”
Pipeline and cash

What's next for AVIR, and how long its cash lasts

From Atea Pharmaceuticals’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

Q1 2027“Topline results are expected in early Q1 2027 and will provide additional efficacy data across a broader range of HCV genotypes”Trial data · 8-K, Aug 12

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCVPhase 3 · Active · 880 people · main data estimated Dec 2026 · NCT07037277

3 more trials, 1 with data due this year, 1 more milestone and 21 filings, for Pro members.

Cash runway Jun 30 balance sheet

About 5 quarters

$219M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's own estimate is “through 2027” (8-K, Jan 8).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Nov 7, 2024)
  • At-the-market share sales program (S-3, filed Nov 7, 2024)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: the amounts, and the share count against a year ago.

Insiders

Director Polly A. Murphy bought 6,100 shares on May 18.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when Jean-Pierre Sommadossi buys or sells

For Pro members: every trade, and Jean-Pierre Sommadossi’s 6 filings and quotes.

Get an optional alert when AVIR files news on its trialsFree for 24 hours. No account needed.

See every upcoming FDA date →

Biotech dates

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

8 more FDA dates and 114 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Quality Score

Why AVIR scores 3

Below AverageChoppy, 3 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

  • +3Chart checks 3 of 14 firing right now, one point each
  • +2Long-term trend above a rising 200-⁠day average
  • Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Size, Growth, Dilution, Volatility, Persistence, and News.

What every line is worth, and the reason behind it, on AVIR and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:46 PM ET, at least 15 minutes behind. How we rank stocks.

What's next

Expected to report Wed Nov 11, after the close

What would turn AVIR's score around: 6 things, for Pro members

Alert me when AVIR's Quality Score turns up

Free for 24 hours. No account needed. Then keep going with a free account.

Pro

Here is what Pro members see.

Every stock has a live page like this, AVIR included: the price in real time, the full chart, all 14 checks, and every line of its score.

AMD's page for Pro members on a phone, recorded live: the price changes as it trades, beside its Quality Score and its rank, with the bid and ask under it and a year of candles below
The same page for Pro members, on AMDThe live price and the full chart, with the Quality Score drawn under it and the line that drives it.
The Score tab on a phone: how AMD's Quality Score adds up from price action, the company, and signals, its rank, and the chart checks by group, trend, volume, tight range, and buying
Every line of the scoreWhat each part adds, and all 14 checks by group, on AVIR and every other stock.
The New alert form on a phone: watch one name, AMD, when its Quality Score is at least 20, sent by the bell on the site, a push notification, and email, with the Save alert button
Your own optional alertsPick what to watch, AVIR or your whole watchlist, and when: a Quality Score, a price, a filing. It comes by push, email, or the bell.
  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.
The 14 checks

AVIR has 3 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown
MA FAN21 EMAW.EMAHH/HL52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown
VOLVDUU/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown
ATR SQZSQUEEZENR7

The daily range is tight against its own recent history.

Buying1 of 3 shown
OBV+CLOSE HISPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on AVIR, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

  • RSI 1444.8

    Above 30, below 50.

  • MACD (12, 26, 9)Below signal

    Crossed below its signal line 17 sessions ago.

  • 50-day average$5.21

    The price is 1.5% below it.

  • 200-day average$4.82

    The price is 6.4% above it. The 50-day is above the 200-day, since Dec 26, 2025.

  • ADX 1412.9

    Under 25, with +DI below -DI.

  • Support$5.12

    Swing low from Sep 15, 0.2% below the price.

  • Resistance$5.64

    Swing high from Aug 21, 9.9% above the price.

  • Bollinger Bands (20, 2)Inside

    The bands run from $4.92 to $5.69.

  • Volume0.8x

    Against its 20-day average, for the time of day.

Its industry

How AVIR ranks in Biotech

AVIR is #96 of 300 by Quality Score. The top three are shown with their scores, and more by name.

More in Biotech, on the Healthcare page

Earnings

When does AVIR report earnings, and what happens after?

Expected to report Wed Nov 11, after the close (in 40 days). Not yet confirmed by the company.

The company

About Atea Pharmaceuticals

Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

55 employeesBoston, MAateapharma.com

Pro

Every line of the score, on every stock.

  • Real-time prices, no delay
  • Every line of AVIR's score, with the points and the reason
  • All 14 checks on AVIR and on all 3,243 stocks
  • Every stock ranked, with the chart
  • Every filing, and optional alerts on AVIR
See all 14 checks on AVIRFree for 24 hours. No account needed. Then keep going with a free account.
Questions

Straight Answers.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.